CME/CE
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Episodes 76-90 of 745
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast ReplayOptimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Burden and pathophysiology of APOL1 kidney disease
KDIGO Conversations in NephrologyBurden and pathophysiology of APOL1 kidney disease
APOL1 Screening and Early Detection: Patient and Clinician Perspectives
KDIGO Conversations in NephrologyAPOL1 Screening and Early Detection: Patient and Clinician Perspectives
Pruritus In PN and AD: Challenge How You Manage Itch
CME/CEPruritus In PN and AD: Challenge How You Manage Itch
Diagnosing and Treating IBS: It Begins With One Simple Question
CME/CE Broadcast ReplayDiagnosing and Treating IBS: It Begins With One Simple Question
Women’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
CME/CE Broadcast ReplayWomen’s Sleep Health – Addressing Gaps in OSA Diagnosis and Treatment Across Life Stages
- advertisement
Current & Emerging Therapies: Treating & Preventing Hereditary Angioedema Attacks in Children & Adults
CME/CECurrent & Emerging Therapies: Treating & Preventing Hereditary Angioedema Attacks in Children & Adults
Understanding Endocrine Resistance in HR+/HER2- mBC
MinuteCE®Understanding Endocrine Resistance in HR+/HER2- mBC
PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
MinuteCE®PI3K Pathway Inhibition in HR+/HER2- mBC: Mechanistic Insights
Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
MinuteCE®Comprehensive Biomarker Testing in mBC Informs Clinical Decision Making
Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
MinuteCE®Double Take: Pivotal Data Evaluating PI3K Inhibitor/Endocrine Therapy Regimens in mBC
- advertisement
Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
MinuteCE®Triple Threat: Key Data on Simultaneous Estrogen, CDK4/6, and PI3K Inhibition in mBC
Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
MinuteCE®Case in Point: Applying PI3K Combinations in Early Recurrent HR+/HER2- mBC
PI3K Pathway Inhibitors: Safety and Tolerability Profiles
MinuteCE®PI3K Pathway Inhibitors: Safety and Tolerability Profiles



































































